Ashlee N Janusziewicz, Shannon N Glueck, Sophia Y Park, Dien N Nguyen, Susan C Rimmel, Laurelle A Cascio, Gina Y Doh, Garrette F Martin-Yeboah
PURPOSE: To provide an overview of compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and to describe the pharmacist's role within the US Food and Drug Administration's (FDA's) Compounding Incidents Program, whose efforts are aimed at protecting the public against poor-quality compounded drugs through surveillance, review and response to adverse events and complaints. SUMMARY: Compounded drugs may serve an important medical need for patients who cannot be treated with medications approved by FDA; however, compounded drugs are not approved by FDA and are not subject to premarket review for safety, efficacy, or manufacturing quality; thus, they may pose safety risks to patients...
July 22, 2021: American Journal of Health-system Pharmacy: AJHP